Compare Stryker Corporation (SYK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs ProShares UltraPro S&P500 — how do they compare? Stryker Corporation trades at $277.33 (market cap $106.24B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: Stryker Corporation is far larger — about 19.1× ProShares UltraPro S&P500's market cap, and Stryker Corporation pays a 1.27% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and ProShares UltraPro S&P500 for 29 Days on average.
| SYK | UPRO | |
|---|---|---|
Market Cap | $106.24B | $5.55B |
Volume | 2,982,001 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.35 | $157.66 |
52-Week Low | $269.75 | $89.29 |
Typical Hold Time | 21 Days | 29 Days |
Enterprise Value | $117.70B | — |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $276.97, up 0.57% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 64.98% gross margins and 14.43% net income margin, though recent Q1 2026 earnings missed expectations. Analyst consensus remains strongly bullish with 71% buy ratings and $368.11 price target, representing 33% upside potential. Recent news highlights ongoing legal investigations regarding manufacturing issues that caused an 8.8% stock drop in September 2026.
SYK presents a compelling investment case with robust fundamentals and strong analyst support, though near-term headwinds from legal scrutiny and manufacturing challenges create uncertainty. The stock's current valuation at 28.7 P/E appears reasonable given growth prospects, but investors should monitor Q3 2026 earnings results on October 29 for confirmation of business recovery from recent setbacks.
UPRO trades at $153.19, down 1.3% on the day, with technical indicators showing a bullish moving average trend but neutral oscillators. The stock faces resistance at $155 and support at $151. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment around the broader market environment.
The outlook for UPRO is influenced by broader market dynamics, with Wall Street expecting continued S&P 500 gains but facing headwinds from concentration risks and economic uncertainty. Key opportunities include potential year-end rallies, while risks involve market volatility and earnings growth slowdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
